Mitomycine Substipharm (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside cancer cells it is reduced to a reactive form that creates covalent cross‑links between DNA strands, blocking DNA synthesis and transcription. This interference triggers programmed cell death, especially in rapidly dividing tumor cells.

The exact dose and schedule are determined by the prescribing oncologist based on the patient’s clinical condition, bladder size, and prior treatments. Intravesical regimens typically involve a single‑dose instillation repeated weekly for several weeks, but the prescriber sets the precise regimen.

Mitomycin is classified as potentially harmful to a developing fetus and is generally avoided during pregnancy unless the therapeutic benefit outweighs the risk. Limited data exist for breastfeeding, and because systemic absorption can occur, use while nursing is not recommended without specialist advice.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The principal alternative for non‑muscle invasive bladder cancer is intravesical Bacillus Calmette‑Guérin (BCG) immunotherapy. Mitomycin provides a chemotherapeutic approach that directly damages DNA, while BCG stimulates an immune response. Choice depends on tumour characteristics, prior treatment response, and patient tolerance to side‑effects.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, allow the solution to reach room temperature if required, and handle it in a sterile environment to maintain aseptic conditions.

Mitomycine Substipharm is given by intravesical instillation. After transurethral resection of bladder tumours, the solution is introduced into the bladder through a catheter and retained for a prescribed dwell time, usually 1–2 hours, before being drained.

Serious risks include systemic absorption leading to bone‑marrow suppression (pancytopenia), severe infections due to neutropenia, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Prompt monitoring of blood counts and renal function is essential to detect these complications early.

Patients with known hypersensitivity to mitomycin, active urinary tract infection, bladder perforation, severe renal impairment, or uncontrolled systemic infection should avoid this therapy. Additionally, pregnant women should not receive it unless the potential benefit justifies the risk.